Elion Therapeutics (formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life-threatening invasive fungal infections (IFIs), announced it has closed a $81 million Series B funding round led by Deerfield Management (Deerfield) and the AMR Action Fund. Additional investors include Illinois Ventures.